Verified Nov 2026
Other
·

Gaithersburg, Maryland
·
Since 1987
Novavax is a biotechnology company founded in 1987 and headquartered in Gaithersburg, Maryland, with 500-1,000 employees and estimated revenue of $1-5 billion. The company develops and commercializes vaccines for serious infectious diseases, including its protein-based COVID-19 vaccine approved by the FDA in May 2025. Novavax operates facilities in Maryland, Sweden, and the Czech Republic and generated approximately $0.7 billion in revenue in fiscal 2024.
Novavax at a glance
Revenue
$1-5B
Est. band
Employees
500-1,000
Founded
1987
Headquarters
Gaithersburg, Maryland
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Overview
Novavax is a biotechnology company founded in 1987 and headquartered in Gaithersburg, Maryland, with 500-1,000 employees and estimated revenue of $1-5 billion. The company develops and commercializes vaccines for serious infectious diseases, including its protein-based COVID-19 vaccine approved by the FDA in May 2025. Novavax operates facilities in Maryland, Sweden, and the Czech Republic and generated approximately $0.7 billion in revenue in fiscal 2024.
At a glance
Attribute | Detail |
|---|---|
Founded | 1987 |
Headquarters | Gaithersburg, Maryland |
Employees | 500-1,000 |
Revenue | $1-5B (estimated) |
What Novavax makes
The company utilizes proprietary Matrix-M adjuvant technology and nanoparticle protein-based platforms to enhance immune responses in vaccines targeting influenza, RSV, Ebola, and malaria.
Products and capabilities described on the company's own site include LED (source: novavax.com).
Latest developments
2026-11-05 — Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights - Nov 5, 2026 (novavax.com)
2026-08-06 — Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights - Aug 6, 2026 (novavax.com)
2026-05-06 — Novavax Reports First Quarter 2026 Financial Results and Operational Highlights - May 6, 2026 (novavax.com)
2026-02-26 — Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Feb 26, 2026 (novavax.com)
2026-01-20 — Novavax signs licensing agreement with Pfizer for vaccine development | Reuters (reuters.com)
2025-10-22 — Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy (novavax.com)
Facilities
Novavax is headquartered in Gaithersburg, Maryland. Public sources also reference these locations:
Gaithersburg, Md — novavax.com
Company details
Novavax is publicly traded on NASDAQ under ticker NVAX and maintains operations across North America and Europe to support manufacturing and development activities. Novavax was founded in 1987, has an estimated 500-1,000 employees, and is headquartered in Gaithersburg, Maryland.
Frequently asked questions
What does Novavax do?
Novavax is a biotechnology company founded in 1987 and headquartered in Gaithersburg, Maryland, with 500-1,000 employees and estimated revenue of $1-5 billion. The company develops and commercializes vaccines for serious infectious diseases, including its protein-based COVID-19 vaccine approved by the FDA in May 2025. Novavax operates facilities in Maryland, Sweden, and the Czech Republic and generated approximately $0.7 billion in revenue in fiscal 2024.
Where is Novavax headquartered?
Novavax is headquartered in Gaithersburg, Maryland (21 Firstfield Rd, Gaithersburg, Maryland, 20878-1757).
When was Novavax founded?
Novavax was founded in 1987.
How big is Novavax?
Novavax has an estimated 500-1,000 employees, with revenue in the $1-5B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
